XASE
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q2 2026 | — | -0.67 | — | $0 | — | +0.70% | -0.70% | — |
| 2026-02-18 | Q1 2026 | — | -0.68 | — | $0 | — | +1.05% | -15.25% | -33.59% |
| 2025-12-29 | Q4 2025 |
| — |
| 0.07 |
| — |
| $0 |
| — |
| — |
| — |
| — |
| 2025-02-14 | Q1 2025 | — | -0.11 | — | $0 | — | +6.91% | -5.04% | -31.87% |
| 2025-01-13 | Q4 2024 | -0.11 | -0.09 | +18.18% | $0 | ✅ Beat | -2.41% | -5.11% | +0.17% |
| 2024-08-15 | Q3 2024 | -0.13 | -0.14 | -7.69% | $0 | ❌ Miss | -0.88% | -2.63% | +0.88% |
| 2024-05-16 | Q2 2024 | — | -0.14 | — | $0 | — | -9.29% | -9.29% | -10.71% |
| 2024-02-14 | Q1 2024 | — | -0.14 | — | $0 | — | — | — | — |
Showing last 8 quarters.